Vertex Pharmaceuticals Incorporated with ticker code (VRTX) have now 25 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between $577.00 and $325.00 with the average target price sitting at $467.42. Given that the stocks previous close was at $437.49 this is indicating there is a potential upside of 6.8%. Also worth taking note is the 50 day moving average now sits at $408.97 while the 200 day moving average is $387.69. The company has a market capitalization of 113.71B. The stock price is currently at: $440.64 USD
The potential market cap would be $121,487,611,349 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 28.58, revenue per share of $39.49 and a 12.82% return on assets.
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF). Its pipeline includes mid- and late-stage clinical programs in sickle cell disease, beta thalassemia, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, and alpha-1 antitrypsin deficiency, and earlier-stage programs in diseases such as muscular dystrophies. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). The Company has a pipeline of investigational small molecule, cell and genetic therapies in other serious diseases where it has deep insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, pain, type 1 diabetes, alpha-1 antitrypsin deficiency and Duchenne muscular dystrophy.
